Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apotex Licenses Exclusive Canadian Rights to Qutenza from Grünenthal
Details : Apotex will have the exclusive Canadian rights to Qutenza (capsaicin), a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 24, 2025
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Averitas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Averitas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Grünenthal Completes Recruitment for QUTENZA® Post-Surgical Neuropathic Pain Trial
Details : Qutenza (capsaicin) topical patch is approved for neuropathic pain associated with postherpetic neuralgia and diabetic peripheral neuropathy, being investigated for post-surgical neuropathic pain.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 07, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Capsaicin in Digital Osteoarthritis Versus Control
Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Hand.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 06, 2024
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Grunenthal
Deal Size : Inapplicable
Deal Type : Inapplicable
Thermosensitivity of a Topical Palmitated Formulation of Capsaicin
Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain Management.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
April 07, 2022
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.
Details : Capsaicin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Neuropathies.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 31, 2021
First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain
Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 10, 2021
Lead Product(s) : Capsaicin,Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Valens Company
Deal Size : Undisclosed
Deal Type : Agreement
The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand
Details : LivRelief is a growing line of cannabis-infused topical creams created using natural ingredients which utilize a proprietary transdermal delivery system, allowing cannabinoids to reach targeted areas and designed for deep penetration.
Product Name : LivRelief
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : Capsaicin,Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Valens Company
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
